CHCWM – Cancer & Hematology Centers of West Michigan

NGM438 (NGM Biopharmaceuticals)

Description:  A Phase 1 / 2 Dose Escalation/Expansion Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors

Mechanism of Action:  Binds human LAIR1 and inhibits interactions between this receptor and its ligand collagen (preventing downregulation of innate and adaptive cellular immune responses)

Target Patient Population:   Most Solid Tumors

Study Design:  Drug is given IV every 3 weeks